The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin…
- Investigator
- William Slayton
- Ages
- 3 Years - 39 Years
- Sexes
- All